Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Annovis Bio Inc.
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
July 1, 2026
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 24, 2026
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 24, 2026
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
May 23, 2026
Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026
May 22, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
May 6, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 29, 2026
1
2
Next Page
→